Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07815574 |
| Title | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma (SCOPE Plus) |
| Acronym | SCOPE Plus |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Scancell Ltd |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | GBR |